RJA
MTNB icon

Raymond James & Associates’s Matinas BioPharma MTNB Stock Holding History

Raymond James & Associates’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-440
Closed -$18K – 4144
2022
Q1 		$18K Buy
440
+170
+63% +$6.26K ﹤0.01% 4019
2021
Q4 		$14K Buy
+270
New +$14.4K ﹤0.01% 4055
2019
Q4 		– Sell
-340
Closed -$11K – 3718
2019
Q3 		$11K Buy
340
+90
+36% +$3.25K ﹤0.01% 3559
2019
Q2 		$11K Buy
+250
New +$12K ﹤0.01% 3582
2017
Q2 		– Sell
-709
Closed -$98K – 3406
2017
Q1 		$98K Buy
+709
New +$116K ﹤0.01% 3072

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Raymond James & Associates's MTNB Position: Q2 2022 in Review

Raymond James & Associates sold out of Matinas BioPharma (MTNB) in Q2 2022, closing a stake of 440 shares — an estimated $18K sold.

Raymond James & Associates first reported a position in MTNB in Q1 2017 and held it in 5 quarters. The position peaked at $98K in Q1 2017. 50 funds tracked by Wall St. Rank hold MTNB as of Q2 2022.

  • Raymond James & Associates reported no remaining Matinas BioPharma position as of Q2 2022 after selling out during the quarter.
  • Raymond James & Associates sold 440 Matinas BioPharma shares in Q2 2022, an estimated $18K.
  • Raymond James & Associates first reported a position in Matinas BioPharma in Q1 2017 and held it in 5 quarters.
  • Raymond James & Associates's Matinas BioPharma position peaked at $98K in Q1 2017.
  • 50 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2022.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.